Sunday 1 April 2012

6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors

Abstract: and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.






Compounds of the formula ...






USPTO Applicaton #: #20120077979 - Class: 544350 (USPTO)

Read more ...

No comments:

Post a Comment